BioSpace News Archive

Enterome announces the presentation of new clinical data from its Phase 2 trial evaluating its lead OncoMimics™ immunotherapy candidate EO2401 in combination with an immune checkpoint inhibitor +/- an anti-VEGF therapy with anti-edema properties, in patients with first progression/recurrence of glioblastoma, at the upcoming American Society of Clinical Oncology Annual Meeting.

Design Therapeutics, Inc. reported that management will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET in NYC.

Caris Life Sciences® announced that Memorial Sloan Kettering Cancer Center, one of the world’s premier cancer centers, has joined the Caris Precision Oncology Alliance™ and will collaborate with Caris on various research projects.

AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced a strategic plan to further develop and operationalize the StemPrintER assay.

Violet Therapeutics, Inc., a therapeutics company utilizing novel proprietary platforms for the identification of cell-cell interaction mechanisms, announces the successful closing of a $10.6 million seed funding round.

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX) today announced that it has received a license from the New York State Department of Health to act as a tissue bank for the processing of mesenchymal stem cells from autologous donors.

Verrica Pharmaceuticals Inc. announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Healthcare Conference, which is being held at the New York Marriot Marquis from June 7-9, 2023.

Selecta Biosciences, Inc. (NASDAQ: SELB) today announced the presentation of positive data from the Phase 3 DISSOLVE I and DISSOLVE II double-blind, placebo-controlled studies of SEL-212 in patients with chronic refractory gout.

IGM Biosciences, Inc. announced that the U.S. Food and Drug Administration has cleared two Investigational New Drug applications for imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, enabling the initiation of Phase 1b studies in both severe systemic lupus erythematosus and severe rheumatoid arthritis.

Sensei Biotherapeutics, Inc. announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Wednesday, June 7, 2023 at 9:30 a.m. ET.